Cargando…
An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke. As a result, atrial fibrillation patients are risk-stratified using the CHADS(2) or CHA(2)DS(2)-VASc scoring systems. Those at int...
Autores principales: | Acharya, Tushar, Deedwania, Prakash |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422295/ https://www.ncbi.nlm.nih.gov/pubmed/26019695 http://dx.doi.org/10.2147/CE.S61441 |
Ejemplares similares
-
Cost-effectiveness of edoxaban versus rivaroxaban for stroke prevention in patients with nonvalvular atrial fibrillation (NVAF) in the US
por: Miller, Jeffrey D, et al.
Publicado: (2016) -
An evidence-based review of apixaban and its potential in the prevention of stroke in patients with atrial fibrillation
por: Deedwania, Prakash, et al.
Publicado: (2012) -
Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with Coronary Artery Disease
por: Fukamachi, Daisuke, et al.
Publicado: (2022) -
Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015) -
Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure
por: Nabeta, Takeru, et al.
Publicado: (2021)